Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 18/20 | 0.48 |
| ▸ | CTSD | P07339 | 8/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL2285659 | 0.95 | BACE1 (0.44) | BACE1CTSDGABRG2GABRB3GABRA5 | |
| SCHEMBL7870302 | 0.90 | BACE1 (0.55) | BACE1CTSDBACE2CTSB | |
| SCHEMBL7862973 | 0.87 | BACE1 (0.48) | BACE1CTSDKCNH2BACE2CTSB | |
| SCHEMBL2277183 | 0.86 | BACE1 (0.66) | BACE1CTSDKCNH2 | |
| SCHEMBL2277191 | 0.86 | BACE1 (0.66) | BACE1CTSDKCNH2 | |
| SCHEMBL2282094 | 0.85 | BACE1 (0.66) | BACE1CTSDKCNH2BACE2 | |
| SCHEMBL2282086 | 0.85 | BACE1 (0.66) | BACE1CTSDKCNH2BACE2 | |
| Formic Acid SCHEMBL2281075 | 0.85 | BACE1 (0.50) | BACE1CTSDBACE2CTSB | |
| SCHEMBL7870320 | 0.84 | BACE1 (0.67) | BACE1CTSDKCNH2BACE2 | |
| SCHEMBL7864861 | 0.83 | BACE1 (0.69) | BACE1CTSDKCNH2BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989449-B2 | 4,5-dihydro-oxazol-2-yl amine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989449-B2 | 4,5-dihydro-oxazol-2-yl amine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20090209529-A1 | 4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-20 | — | — | US | disclosed |
| US-20090209529-A1 | 4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209529-A1 | 4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES | BACE2, BACE1, PSEN2 | BACE1 2/4885CTSD 721/4885GABRG2 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.